an open label&#44

2 trials

Sponsors

US National Institutes of Health (NIH), CELLTRION, Inc.

Conditions

Ankylosing Spondylitis&#44HIV Infection Prevention HIV Combination prevention Young MSM PrEP Effectiveness Cost&#45

Phase 4

Post-Marketing Surveillance of REMSIMAâ„¢ 100 mg. (Infliximab)(monoclonal antibody, recombinant) to Evaluate its Safety and Efficacy in Thailand

RecruitingTCTR20170817005

CELLTRION, Inc.Ankylosing Spondylitis&#44

Start: 2017-08-18Target: 30Updated: 2026-08-03

Unknown Phase

Combination Prevention Effectiveness Study for Young MSM

RecruitingTCTR20170408001

US National Institutes of Health (NIH)HIV Infection Prevention HIV Combination prevention Young MSM PrEP Effectiveness Cost&#45

Start: 2017-10-10Target: 1240Updated: 2026-08-03